Global Pharma, Biotech and Diagnostics Merger and Acquisition Terms and Agreements Deals 2012-2018

Dublin, March 08, 2018 -- The "Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018" report has been added to ResearchAndMarkets.com's offering.

The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology, diagnostic and other lifescience sectors. Fully revised and updated, the report provides details of M&A agreements from 2012 to 2018.

The report provides a detailed understanding and analysis of how and why companies enter M&A deals. The majority of deals are acquisitions whereby the acquirer acquires the target company in a cash and/or equity transaction.

Merger and acquisition is a constant activity within the biopharma sector. In the past, biopharma companies have sought to merge or acquire competitor companies in order to achieve critical mass both in R&D and sales and marketing, thus ensuring continued growth and dominance in a highly competitive and global marketplace.

In 1987, the largest ten companies were responsible for approximately twelve percent of global pharmaceutical sales. By 2002, this figure had become nearly fifty percent. This concentration was principally due to big pharma mega mergers.

The rewards offered for the successful marketing and sale of a block buster drug are enormous, therefore it is not surprising to see big pharma seeking ways of maximizing returns. Licensing has often been a means of achieving such global presence, but increasingly big pharma has sought to acquire its way into the major pharmaceutical markets. Until recently the mega merger was a popular means of growing presence globally; however the last few years have seen a concentration on smaller acquisitions to bolster R&D pipelines.

This report focuses on M&A between big pharma-big pharma, big pharma - smaller company, big biotech-big biotech, big biotech - smaller company, and smaller company-smaller company, providing a detailed insight into all such deals.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in M&A dealmaking

2.1. Introduction
2.2. Difference between merger and acquisition deals
2.3. Trends in M&A deals since 2012
2.4. Key M&A trends
2.5. Option to acquire the new acquisition?
2.6. When M&A can be useful
2.7. Attributes of M&A deals
2.8. Partnering deals with M&A component
2.9. Big pharma mega mergers - are we at the end of the road?
2.10. Accessing innovation through M&A
2.11. The emerging role of private equity in M&A
2.12. Implementing M&A transactions
2.13. Joint ventures as alternative to M&A
2.14. The future of M&A in biopharma

Chapter 3 - Overview of M&A deal structure

3.1. Introduction
3.2. Pure versus multi-component acquisition deals
3.3. Pure M&A agreement structure
3.4. Acquisition as part of a wider alliance agreement
3.5. Merger agreements

Chapter 4 - Leading M&A deals

4.1. Introduction
4.2. Top M&A deals by value

Chapter 5 - Top 50 most active M&A dealmakers

5.1. Introduction
5.2. Top 50 most active M&A dealmakers

Chapter 6 - M&A contract directory 2012- 2018

6.1. Introduction
6.2. M&A deals with contracts 2012 to 2018

Appendices

Appendix 1 - M&A deals by company A-Z
Appendix 2 - M&A deals by industry sector
Appendix 3 - M&A deals by therapy area
Appendix 4 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/research/tq8rqt/global_pharma?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Biotechnology, Pharmaceuticals, Diagnostics